Researchers Urge Full Testing for Medicinal Products Susceptible to Dose Dumping

by Rajashri on  September 25, 2009 at 8:18 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Dose dumping is the name given to a process where drugs release their contents very quickly in an unwanted manner. Controlled release pills and capsules that show a tendency in the standard laboratory test toward releasing their medicine in a faster and potentially unsafe manner in patients who have consumed alcohol should be withheld from the market until proven safe with testing in people.
 Researchers Urge Full Testing for Medicinal Products Susceptible to Dose Dumping
Researchers Urge Full Testing for Medicinal Products Susceptible to Dose Dumping

That's the conclusion of a review of existing studies in the September-October issue of ACS' Molecular Pharmaceutics, a bi-monthly journal.

In the article, Hans Lennernäs analyzed the gastrointestinal factors that may contribute to dose dumping when a vulnerable formulation interacts with alcohol present in the stomach. However, these factors are highly variable and depend on individual drinking behavior, whether food is present in the stomach, and other circumstances. That makes it "almost impossible" to predict whether a patient will experience an overdose as a result of dose dumping.

Lennernäs thus concludes that when laboratory testing of a product indicates that the drug will be released more quickly than intended, the product also should be tested in humans, or it should be re-formulated. Indeed, Lennernäs believes that lab testing over a two hour period in a range of alcohol strengths is an "absolute minimum standard" in screening for dose dumping because products with a problem in the lab may also be dangerous to patients. Lennernäs cites as an example a formulation of the pain medication hydromorphone, which was removed from the U.S. market when testing revealed that alcohol intake caused the risk of overdose. He noted, however, that there is currently a generic oxycodone product on the market in the European Union which will "most likely" lead to dose dumping in patients.



Source: Eurekalert
RAS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive